Thomas Wilcox, DO
Pulmonary Disease · Boulder, CONPI 1073629507
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $734 of the $1,097 with a category attached, or 66.9%. 14 manufacturers reported payments, led by Novartis at 48.3% of the total. Reporting peaked in 2019 at $568 and has fallen 87.3% since, to $72 in 2025. That places this record below the midpoint for pulmonary disease clinicians in CO, where the typical reported total is $772.
Across 25 payments — averaging $43.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$530
- AstraZeneca$126
- Inspire Medical Systems, Inc.$80
- Actelion Pharmaceuticals US, Inc.$78
- Aerin Medical Inc.$56
- Resmed Corp$47
- plus $180 from 8 others
Across 180 payments — averaging $3873.96 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sanofi US Services Inc.$407K
- Chiesi USA, Inc.$189K
- AstraZeneca$82K
- Novartis$19K
What the payments were for
- Travel & lodging$31028%
- Food & beverage$73467%
- Education$535%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 4 | $530 |
| AstraZeneca | 2 | $126 |
| Inspire Medical Systems, Inc. | 2 | $80 |
| Actelion Pharmaceuticals US, Inc. | 4 | $78 |
| Aerin Medical Inc. | 2 | $56 |
| Resmed Corp | 3 | $47 |
| Genentech USA, Inc. | 1 | $38 |
| Lilly USA, LLC | 1 | $31 |
| Avadel CNS Pharmaceuticals, LLC | 1 | $25 |
| Bayer | 1 | $21 |
| Pulmonx Corporation | 1 | $17 |
| Itamar Medical Inc | 1 | $17 |
| ZOLL Respicardia, Inc. | 1 | $16 |
| Sanofi | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- QBW251$460
How this compares
$1,097 in reported general payments places this provider in the 50th percentile of 248 pulmonary disease providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 511 | $442,826 |
| Breo ElliptaFluticasone/Vilanterol | 402 | $237,951 |
| Prolastin CAlpha-1-Proteinase Inhibitor | 13 | $226,598 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 246 | $163,075 |
| Pirfenidone | 38 | $70,777 |
| Advair HfaFluticasone Propion/Salmeterol | 44 | $24,282 |
| Arnuity ElliptaFluticasone Furoate | 56 | $15,689 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 115 | $15,095 |
| EliquisApixaban | 16 | $13,868 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 22 | $13,011 |
| Spiriva HandihalerTiotropium Bromide | 21 | $11,147 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 15 | $9,618 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 207 | $5,714 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 12 | $5,418 |
| SymbicortBudesonide/Formoterol Fumarate | 13 | $4,875 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaBreztri Aerosphere, Bevespi Aerosphere, Symbicort | $126 | $19,91140 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 248 pulmonary disease providers in Colorado.
Other pulmonary disease in Boulder
- Samuel BerngardBoulder$73K
- Michael WechslerDenver$2.7M
- Ronald BalkissoonDenver$1.2M
- David SchwartzAurora$471K
- Vamsi GunturDenver$310K
- Kevin BrownDenver$299K
- Rebecca KeithDenver$248K
- Joshiah GordonPueblo$208K
- Marjorie GeorgeDenver$192K
- Everett SutherlandDenver$174K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.